FDA removes black-box warnings on three estrogen patches

Experts express concern over lack of transparency as the agency cites supply shortages and updated risk profiles for healthy women.

FDA removes black-box warnings on three estrogen patches
Photo: The Guardian

The FDA has removed black-box warnings on three estrogen patches, a move that has drawn criticism from experts regarding a lack of transparency.

The agency did not convene an advisory committee and offered few details on the scientific basis for the decision during a press briefing. When journalists asked for the evidence behind the decision, officials said it could be provided later.

Sarah Ibrahim, deputy center director for regulatory programs of the FDA’s Center for Drug Evaluation and Research, said the black-box warnings painted a broad and, in some cases, overstated pictures of risk. She stated that updated evidence shows the risk-benefit profile looks meaningfully different for many healthy women under 60 and within 10 years of menopause onset.

Officials highlighted that patients are facing shortages for menopause hormone treatments. Sarah Ibrahim said that after label changes in February, demand for estradiol patches increased significantly, making it difficult for patients to find their usual patches at pharmacies. Dorothy Fink, deputy director of the National Institute of Child Health and Human Development, said the agency is working with manufacturers to strengthen supply and improve access, noting that manufacturing of estrogen patches has doubled over the past year.

Reshma Ramachandran, an assistant professor and health services researcher at Yale School of Medicine, said the blanket removal of warnings regarding risks of breast cancer and cardiovascular disease without clear justification can be misleading and underplays real potential harms. She noted there are particular risks for certain groups, such as those with histories of hormone-sensitive cancers.

The FDA is also exploring the possibility of offering vaginal estrogen products over the counter.

Key facts

  • The FDA removed black-box warnings from three estrogen patches without convening an advisory committee.
  • Manufacturing of estrogen patches has doubled over the past year.
  • The agency is exploring offering vaginal estrogen products over the counter.

Three perspectives

Neutral

The FDA removed black-box warnings on three estrogen patches while citing updated risk-benefit profiles for certain women and addressing treatment shortages.

Positive

The agency is working with manufacturers to strengthen supply and improve access to menopause hormone treatments.

Negative

Experts expressed concern that the removal of warnings regarding breast cancer and cardiovascular disease risks lacks transparency and could be misleading for patients.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition